This is supported by the finding reported in patients with spondyloarthritis (SpA) treated with TNF-α antagonist: serum YKL-40 concentrations decreased during successful anti-TNF-α treatment whereas YKL-40 levels remained high in non-responding patients [41]. The gene discussed is TNF; the disease is spondyloarthropathy.